Kalos Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Kalos Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-405	Closed	-$24K	–	266
2020 Q3	$24K	Hold	405	–	–	0.01%	229
2020 Q2	$52K	Hold	405	–	–	0.02%	210
2020 Q1	$24K	Buy	405 +33	+9%	+$3.23K	0.01%	201
2019 Q4	$48K	Hold	372	–	–	0.02%	199
2019 Q3	$46K	Hold	372	–	–	0.02%	193
2019 Q2	$111K	Buy	372 +18	+5%	+$7.51K	0.05%	182
2019 Q1	$159K	Sell	354 -59	-14%	-$25.8K	0.1%	141
2018 Q4	$179K	Buy	413 +25	+6%	+$15.5K	0.09%	166
2018 Q3	$308K	Buy	388 +177	+84%	+$117K	0.17%	117
2018 Q2	$137K	Hold	211	–	–	0.06%	187
2018 Q1	$137K	Buy	+211	New	+$158K	0.08%	112

Other funds holding HTGM

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Kalos Management's HTGM Position: Q4 2020 in Review

Kalos Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2020, closing a stake of 405 shares — an estimated $24K sold.

Kalos Management first reported a position in HTGM in Q1 2018 and held it in 11 quarters. The position peaked at $308K in Q3 2018. 23 funds tracked by Wall St. Rank hold HTGM as of Q4 2020.

Kalos Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Kalos Management sold 405 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2020, an estimated $24K.
Kalos Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 11 quarters.
Kalos Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $308K in Q3 2018.
23 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2020.

Based on Kalos Management's 13F filing for Q4 2020, filed 11 Feb 2021.